

Kyprolis[®] (carfilzomib) – Expanded indication

- On June 30, 2022, the <u>FDA approved</u> Amgen's <u>Kyprolis (carfilzomib)</u>, in combination with <u>Sarclisa[®] (isatuximab-irfc)</u> and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy.
 - Kyprolis is also approved for this indication in combination with <u>Revlimid[®] (lenalidomide)</u> and dexamethasone; or dexamethasone; or <u>Darzalex[®] (daratumumab)</u> and dexamethasone; or <u>Darzalex Faspro® (daratumumab/hyaluronidase-fihj)</u> and dexamethasone.
- Additionally, Kyprolis is approved as a single agent for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one or more lines of therapy.
- The approval of Kyprolis for the expanded indication was based on IKEMA, a randomized, openlabel study in 302 patients with relapsed and/or refractory multiple myeloma. Patients received either Kyprolis in combination with Sarclisa and dexamethasone (Isa-Kd) or Kyprolis and dexamethasone (Kd). Efficacy was based on progression-free survival (PFS).
 - Median PFS was not reached with Isa-Kd vs. 20.27 months with Kd (hazard ratio 0.548, 95% CI: 0.366, 0.822; p = 0.0032).
 - The overall response rate was 86.6% (95% CI: 80.7, 91.2) with Isa-Kd vs. 82.9 (95% CI: 75.1, 89.1) with Kd (p = 0.3859).
- When administered with Sarclisa and dexamethasone, the recommended starting dosage of Kyprolis is 20 mg/m² on cycle 1, days 1 and 2. If tolerated, the dose should be escalated to 56 mg/m² on cycle 1, day 8. Kyprolis is administered intravenously as a 30-minute infusion on days 1, 2, 8, 9, 15, and 16 of each 28-day cycle until disease progression or unacceptable toxicity.
 - Refer to the drug label for complete dosing for this use and Kyprolis' other uses.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews[®] is published by the Optum Rx Clinical Services Department.